NextImmune
Empowering Treatment with Superior Safety and Efficacy in Autoimmune and Transplant Care
Empowering Treatment with Superior Safety and Efficacy in Autoimmune and Transplant Care
NextImmune is a biotechnology startup founded in 2021, with a focus on empowering treatment with superior safety and efficacy in autoimmune and transplant care. The company is committed to advancing the research and development of a new generation of immunosuppressive drugs aimed at treating autoimmune diseases and improving outcomes for organ transplantation. Their goal is to achieve high efficacy and safety without the adverse effects commonly associated with conventional immunosuppressants. The most recent investment in NextImmune was a Fr.150.00K grant investment at 27 June 2022, and the investors involved in this round were Venture Kick. The company operates within the biotechnology and healthcare industries. Overall, NextImmune is positioned as a promising player in the biotechnology field, targeting critical medical needs with innovative solutions. The recent investment from Venture Kick underscores confidence in the potential of NextImmune's approach to developing immunosuppressive drugs for autoimmune diseases and organ transplantation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Fr.150.00K | 1 |
|
27 Jun 2022 |
No recent news or press coverage available for NextImmune.
We care about your data, and we'd love to use cookies make your experience better.